Core Viewpoint - The announcement details a conditional sale agreement between Anselme Limited (the offeror) and Li Jingyang (the seller) for the acquisition of 138.7 million shares of Huakang Biomedical, representing approximately 27.71% of the company's total issued share capital, for a total consideration of HKD 17.4727 million, equating to HKD 0.126 per share, which is a discount of about 68.10% compared to the market price on the announcement date [1][2]. Group 1 - The offeror will acquire 138.7 million shares, representing approximately 27.71% of the total issued share capital of Huakang Biomedical [1]. - Prior to the completion of the transaction, the offeror directly and beneficially owns 121 million shares, which is about 24.13% of the total issued share capital [1]. - Following the completion of the transaction, the offeror, Dr. Zhou, and any parties acting in concert with them will collectively own 259 million shares, representing approximately 51.84% of the total issued share capital [1]. Group 2 - The offeror is wholly owned by Dr. Zhou Xun Yong, who is also the sole director of the offeror [2]. - The company has applied to the Stock Exchange for the resumption of trading of its shares on GEM starting from 9:00 AM on October 10, 2025 [2].
华康生物医学获Anselme Limited收购27.71%股份及折让约68.10%提现金要约 10月10日复牌